T +1 212 819 7884
T +1 617 979 9321
Kevin Adam is a litigation associate in the New York and Boston offices and a member of the firm's Global Competition Group. His practice focuses on complex litigation in the areas of antitrust, intellectual property, and commercial disputes. Kevin represents several leading global pharmaceutical companies, including Allergan and Boehringer Ingelheim, in class action litigation matters at the cutting edge of antitrust and intellectual property, including AGGRENOX®, BOTOX®, DORYX®, NAMENDA®, and ASACOL®. He also has experience advising clients in the aviation and casino industries.
Kevin regularly speaks and writes about antitrust, class actions, and intellectual property. He has published a number of articles in those areas and is a co-author of a book on class actions titled "Deconstructing Rule 23: A Comparison of Massachusetts and Federal Class-Action Litigation."
Kevin also has an extensive pro bono practice, with a particular focus on criminal appellate work. He has represented criminal defendants in New York's Appellate Division and the New York Court of Appeals. Most recently, Kevin successfully vacated a criminal conviction obtained by the New York Attorney General's Office in New York's First Department.
Kevin graduated from Suffolk University Law School summa cum laude in 2012, where he served as Editor-in-Chief of the Suffolk University Law Review. Prior to joining the firm, Kevin worked at the First District Court of Essex County in Salem, Massachusetts and later served as a research assistant for the Honorable John M. Greaney, former Associate Justice of the Supreme Judicial Court of Massachusetts.
Representation of Boehringer Ingelheim in an antitrust class action challenging a patent settlement.
Representation of Allergan/Warner Chilcott in a number of antitrust class actions involving challenges to new-product introductions, patent settlements, and license agreements.
Represented Allergan/Warner Chilcott in litigation brought by competitor Mylan, challenging Warner Chilcott's transition to new versions of its Doryx acne treatment. Kevin and the White & Case team obtained dismissal of all of Plaintiff's claims on summary judgment, representing the first-ever victory for a defendant on a full evidentiary record in a so-called pharmaceutical "product hopping" litigation.
Represented major pharmaceutical clients on appeal in number of circuit courts.
Member of a trial team that represented a global pharmaceutical company in a preliminary injunction hearing in New York in an antitrust action challenging a new-product launch.
Represented Pfizer in Hatch-Waxman patent litigation
Represented a leading internet company in a patent dispute in the Court of Appeals for the Federal Circuit.
"Recent Antitrust Developments: March and April 2015", May 12, 2015: ABA Section of Antitrust Law, Health Care and Pharmaceuticals Committee
Structure or Function? AbbVie Deutschland GmbH & Co. v. Janssen Biotech, Inc. and the Federal Circuit's Structure-Function Analysis of Functionally Defined Genus Claims Under Section 112's Written Description Requirement, 3 Suffolk U. L. Rev. Online 1, 2015
Deconstructing Rule 23: A Comparison of Massachusetts and Federal Class-Action Litigation, Flaschner Judicial Institute, 2013, (co-author with Lisa M. Scalisi and The Honorable John M. Greaney (ret.), Former Associate Justice of the Massachusetts Supreme Judicial Court)
Obviously Obvious: Federal Circuit Reverses District Court's Decision That Online 'Shopping Cart' Patents Are Nonobvious as a Matter of Law—Soverain Software LLC v. Newegg Inc., 1 Suffolk U. L. Rev. Online 9, 2013
Shooting the Messenger: A Common-Sense Analysis of State 'Ag Gag' Legislation Under the First Amendment, 45 Suffolk U. L. Rev. 1167, 2012
Supreme Judicial Court of Massachusetts Fails to Require Statistical Analysis for Nonexclusion DNA Test Results—Commonwealth v. Mattei, 920 N.E.2d 845 (Mass. 2010), 44 Suffolk U. L. Rev. 767, 2011